309 related articles for article (PubMed ID: 35168870)
21. Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis.
Welsner M; Schulte T; Dietz-Terjung S; Weinreich G; Stehling F; Taube C; Strassburg S; Schoebel C; Sutharsan S
Respiration; 2022; 101(8):766-774. PubMed ID: 35598598
[TBL] [Abstract][Full Text] [Related]
22. Use of CFTR modulators in special populations, part 2: Severe lung disease.
Elijah J; Fitzgerald LJ; Phan H
Pediatr Pulmonol; 2023 Dec; 58(12):3386-3392. PubMed ID: 37728222
[TBL] [Abstract][Full Text] [Related]
23. Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.
FitzMaurice TS; McCann C; Nazareth D; Shaw M; McNamara PS; Walshaw MJ
J Cyst Fibros; 2022 Nov; 21(6):1036-1041. PubMed ID: 35101365
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
[TBL] [Abstract][Full Text] [Related]
25. Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.
Aalbers BL; Mohamed Hoesein FAA; Hofland RW; Bronsveld I; Kruijswijk MA; Schotman S; Slingerland CW; Panhuis H; van der Ent CK; Heijerman HGM
Pediatr Pulmonol; 2023 Aug; 58(8):2317-2322. PubMed ID: 37222401
[TBL] [Abstract][Full Text] [Related]
26. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
[No Abstract] [Full Text] [Related]
27. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
28. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
[TBL] [Abstract][Full Text] [Related]
30. Real world outcomes of CFTR modulator therapy in Australian adults and children.
Kuek S; McCullagh A; Paul E; Armstrong D
Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
[TBL] [Abstract][Full Text] [Related]
31. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Hisert KB; Birket SE; Clancy JP; Downey DG; Engelhardt JF; Fajac I; Gray RD; Lachowicz-Scroggins ME; Mayer-Hamblett N; Thibodeau P; Tuggle KL; Wainwright CE; De Boeck K
Lancet Respir Med; 2023 Oct; 11(10):916-931. PubMed ID: 37699420
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
[TBL] [Abstract][Full Text] [Related]
34. Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis.
Bode SFN; Rapp H; Lienert N; Appel H; Fabricius D
Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3271-3277. PubMed ID: 36738326
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
36. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
[TBL] [Abstract][Full Text] [Related]
37. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
[TBL] [Abstract][Full Text] [Related]
38. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
[TBL] [Abstract][Full Text] [Related]
39. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.
Sheikh S; Britt RD; Ryan-Wenger NA; Khan AQ; Lewis BW; Gushue C; Ozuna H; Jaganathan D; McCoy K; Kopp BT
Pediatr Pulmonol; 2023 Mar; 58(3):825-833. PubMed ID: 36444736
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
